Equity incentives and director votes at Biofrontera (NASDAQ: BFRI) 2026 meeting
Biofrontera Inc. has announced its 2026 annual stockholders meeting, which will be held virtually on June 11, 2026. Key proposals include the re-election of two Class II directors, an amendment to increase the share limit of the 2021 Omnibus Incentive Plan from 3,750,000 to 8,750,000 shares, and the ratification of CBIZ CPAs P.C. as the independent auditor for 2026. The expanded equity plan aims to support future stock-based awards for employees, directors, and consultants, enhancing retention and hiring capabilities.
JAN 13·GlobeNewswire▲
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Biofrontera Inc. announced preliminary unaudited revenues for Q4 2025, expecting between $17.0 and $17.5 million, marking its highest quarterly revenue and about 35% year-over-year growth. Full-year 2025 revenues are projected to be between $41.5 and $42.0 million, an increase of 11% to 13%. The company attributes this success to strong execution, continued growth of Ameluz® PDT, and a recent pricing adjustment, with final results expected in March 2026.
NOV 7·GlobeNewswire→
Pelthos Therapeutics Acquires Xepi® ( ozenoxacin ) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
DURHAM, N.C., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ( "Pelthos" ) , today announced it has acquired the U.S. commercialization rights ...
